For decades, global health procurement has mostly relied on centralised multilateral institutions pooling donor funding to purchase and distribute medicines across low and middle-income countries.
While this model of procurement has delivered many successes, it has simultaneously perpetuated inefficiencies, including misaligned priorities, inflexible procurement processes, and an unsustainable reliance on external funding.
